TobraDex
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Synonyms / Brand Names:
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Dosing and Administration
One or two drops instilled into the conjunctival sac(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to one or two drops every two (2) hours. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.
Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation.
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on TobraDex
Return to top
Publication Resources
Most Recent Articles on TobraDex
Review Articles on TobraDex
Articles on TobraDex in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on TobraDex
Return to top
Trial Resources
Ongoing Trials with TobraDex at Clinical Trials.gov
Trial Results with TobraDex
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on TobraDex
Cochrane Collaboration on TobraDex
Cost Effectiveness of TobraDex
Return to top
Media Resources
Powerpoint Slides on TobraDex
Images of TobraDex
Podcasts & MP3s on TobraDex
Videos on TobraDex
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on TobraDex
Discussion Groups on TobraDex
Patient Handouts on TobraDex
Blogs on TobraDex
TobraDex in the News
TobraDex in the Marketplace
Return to top
International Resources
TobraDex en Español
Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
